Difference between revisions of "Glioblastoma"

Jump to navigation Jump to search
(→‎Molecular: wikify + ref)
(→‎Molecular: +chr7/-10)
Line 155: Line 155:
** In cases above 55 years, negative IDH1 R132H immunohistochemistry may be sufficient.
** In cases above 55 years, negative IDH1 R132H immunohistochemistry may be sufficient.


* 70% of IDH-wildtype glioblastoma show chr.7 gain and chr.10 loss.<ref>{{Cite journal  | last1 = Ceccarelli | first1 = M. | last2 = Barthel | first2 = FP. | last3 = Malta | first3 = TM. | last4 = Sabedot | first4 = TS. | last5 = Salama | first5 = SR. | last6 = Murray | first6 = BA. | last7 = Morozova | first7 = O. | last8 = Newton | first8 = Y. | last9 = Radenbaugh | first9 = A. | title = Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. | journal = Cell | volume = 164 | issue = 3 | pages = 550-63 | month = Jan | year = 2016 | doi = 10.1016/j.cell.2015.12.028 | PMID = 26824661 }}</ref>
*Seen in inherited tumor syndromes:
*Seen in inherited tumor syndromes:
**[[Lynch syndrome]]
**[[Lynch syndrome]]